Form 4: Aerovate Therapeutics Officer Sells Shares Under 10b5-1 Plan
SEC Form 4
Marinus Verwijs, Chief Technical Officer of Aerovate Therapeutics, sold shares of common stock and exercised stock options on April 1, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On April 1, 2024, Marinus Verwijs, the Chief Technical Officer of Aerovate Therapeutics, executed transactions involving the company's common stock.
- Verwijs exercised stock options to acquire 5,300 shares at a price of $14.59 per share.
- Concurrently, Verwijs sold 3,796 shares at a weighted average price of $28.8669 and 1,504 shares at a weighted average price of $29.999.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on November 17, 2023.
- Following these transactions, Verwijs directly owns 1,504 shares of common stock and 79,400 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to assess management's confidence in the company's prospects. The use of a 10b5-1 trading plan suggests that these transactions were pre-planned and not based on any specific non-public information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2023-03-21 | 25% of the stock option vested and became exercisable. |
| 2023-11-17 | Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2024-04-01 | Date of transaction: exercise of stock options and sale of common stock. |
| 2032-03-20 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.